Skip to content

Study · Animal study (in vivo) · rat · 1991

5 results

IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass.

Martin AA, Tomas FM, Owens PC, Knowles SE, Ballard FJ, Read LC

The American journal of physiology1 Oct 1991Cited by 16 (Europe PMC)

PMID1928375 (opens in a new tab)DOI10.1152/ajprenal.1991.261.4.f626 (opens in a new tab)PepBankPUB-01928375
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with reduced renal mass, des-(1-3)IGF-I significantly increased body weight gain.

    In plain wordsIn rats with reduced kidney mass, des-(1-3)IGF-I increased weight gain compared with untreated rats.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseBody weight gain
    Study

    ratn: not reported in source

    Subtotally nephrectomized young male rats
    Comparator
    Untreated rats with reduced renal mass
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.9 mg/kg per day · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Body weight gain, food utilization, and nitrogen balance during the treatment period were significantly increased in rats treated with IGF-I at both the lower and higher doses and in those treated with des-(1-3)IGF-I.
    2 context sentences
    Summary · context
    The efficacy of insulin-like growth factor I (IGF-I) in enhancing growth in animals with reduced renal mass was investigated in subtotally nephrectomized young male rats.
    Summary · context
    Recombinant human IGF-I was administered by osmotic minipumps for 7 days at two doses, 0.9 and 2.2 mg.kg body wt-1. day-1, and the truncated analogue of IGF-I, des-(1-3)IGF-I, was given at a dose of 0.9 mg.kg body wt-1.day-1.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with reduced renal mass, des-(1-3)IGF-I significantly increased food utilization.

    In plain wordsIn rats with reduced kidney mass, des-(1-3)IGF-I improved food utilization compared with untreated rats.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseFood utilization
    Study

    ratn: not reported in source

    Subtotally nephrectomized young male rats
    Comparator
    Untreated rats with reduced renal mass
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.9 mg/kg per day · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Body weight gain, food utilization, and nitrogen balance during the treatment period were significantly increased in rats treated with IGF-I at both the lower and higher doses and in those treated with des-(1-3)IGF-I.
    2 context sentences
    Summary · context
    The efficacy of insulin-like growth factor I (IGF-I) in enhancing growth in animals with reduced renal mass was investigated in subtotally nephrectomized young male rats.
    Summary · context
    Recombinant human IGF-I was administered by osmotic minipumps for 7 days at two doses, 0.9 and 2.2 mg.kg body wt-1. day-1, and the truncated analogue of IGF-I, des-(1-3)IGF-I, was given at a dose of 0.9 mg.kg body wt-1.day-1.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with reduced renal mass, des-(1-3)IGF-I significantly increased nitrogen balance.

    In plain wordsIn rats with reduced kidney mass, des-(1-3)IGF-I improved nitrogen balance compared with untreated rats.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseNitrogen balance
    Study

    ratn: not reported in source

    Subtotally nephrectomized young male rats
    Comparator
    Untreated rats with reduced renal mass
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    0.9 mg/kg per day · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Body weight gain, food utilization, and nitrogen balance during the treatment period were significantly increased in rats treated with IGF-I at both the lower and higher doses and in those treated with des-(1-3)IGF-I.
    2 context sentences
    Summary · context
    The efficacy of insulin-like growth factor I (IGF-I) in enhancing growth in animals with reduced renal mass was investigated in subtotally nephrectomized young male rats.
    Summary · context
    Recombinant human IGF-I was administered by osmotic minipumps for 7 days at two doses, 0.9 and 2.2 mg.kg body wt-1. day-1, and the truncated analogue of IGF-I, des-(1-3)IGF-I, was given at a dose of 0.9 mg.kg body wt-1.day-1.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats with reduced renal mass, des-(1-3)IGF-I reduced muscle protein breakdown as indicated by urinary 3-methylhistidine excretion.

    In plain wordsIn rats with reduced kidney mass, des-(1-3)IGF-I reduced muscle protein breakdown, as indicated by a urine marker, compared with untreated rats.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseMuscle protein breakdown
    Study

    ratn: not reported in source

    Subtotally nephrectomized young male rats
    Comparator
    Untreated rats with reduced renal mass
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    0.9 mg/kg per day · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    The improved nitrogen balance in the des-(1-3)IGF-I group could at least partly be explained by a diminished rate of muscle protein breakdown, as indicated by the reduced urinary excretion rate of 3-methylhistidine.
    2 context sentences
    Summary · context
    The efficacy of insulin-like growth factor I (IGF-I) in enhancing growth in animals with reduced renal mass was investigated in subtotally nephrectomized young male rats.
    Summary · context
    Recombinant human IGF-I was administered by osmotic minipumps for 7 days at two doses, 0.9 and 2.2 mg.kg body wt-1. day-1, and the truncated analogue of IGF-I, des-(1-3)IGF-I, was given at a dose of 0.9 mg.kg body wt-1.day-1.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 05AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome

    In rats with reduced renal mass, IGF treatment did not affect carcass composition, without a separate des-(1-3)IGF-I result.

    In plain wordsIn rats with reduced kidney mass, IGF treatment did not change body composition. The abstract gives no separate des-(1-3)IGF-I result.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeCarcass composition
    Study

    ratn: not reported in source

    Subtotally nephrectomized young male rats
    Comparator
    Untreated rats with reduced renal mass
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Carcass composition was not affected by IGF treatment.
    2 context sentences
    Summary · context
    The efficacy of insulin-like growth factor I (IGF-I) in enhancing growth in animals with reduced renal mass was investigated in subtotally nephrectomized young male rats.
    Summary · context
    Recombinant human IGF-I was administered by osmotic minipumps for 7 days at two doses, 0.9 and 2.2 mg.kg body wt-1. day-1, and the truncated analogue of IGF-I, des-(1-3)IGF-I, was given at a dose of 0.9 mg.kg body wt-1.day-1.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.